Background: The recommended drug for moderate to severe chronic rhinitis is intranasal steroids (INS). However, nasal congestion could be refractory and need additional treatments.
Introduction
Chronic rhinitis, including allergic and nonallergic types, is very common in Thailand and worldwide. The recommended drug for moderate to severe forms of chronic rhinitis is intranasal steroids (INS). 1 Despite the efficacy of INS in relieving all nasal symptoms, nasal congestion could occasionally be refractory to treatment as high as 40% of patients, resulting in the need for additional treatments. [2] [3] The higher dose of INS for treating allergic rhinitis showed a slightly greater reduction in symptom score but did not reach statistical significance. 4 Therefore, patients who have already taken INS plus antihistamine and still have nasal congestion may finally undergo surgical treatment such as radiofrequency turbinoplasty or immunotherapy.
Oxymetazoline (Oxymet) is an imidazole derivative which directly acts on -adrenergic receptors in the arterioles of the nasal mucosa. This leads to a decrease in the oedema of nasal turbinates. The duration of action of the drug is up to 12 hours, as shown by rhinomanometry and magnetic resonance imaging on nasal patency. [5] [6] A recent study reported that Oxymet added to the effectiveness of INS in the treatment of allergic rhinitis without the development of rhinitis medicamentosa. 3, 7 However, the combination of INS and Oxymet has never been studied in patients with non-allergic rhinitis who commonly present with nasal congestion. In accordance with previous studies, Oxymet might be helpful to treat nasal congestion while INS prevents the development of rhinitis medicamentosa. [8] [9] Thus, we hypothesised that the combination of high-dose INS and Oxymet would improve nasal congestion for patients with chronic rhinitis, both allergic and non-allergic, compared with INS alone without inducing rhinitis medicamentosa.
Methods
We performed a 6-week, randomised, doubleblind clinical trial in 50 patients, 18 years of age or greater, with chronic rhinitis. Chronic rhinitis including both allergic and non-allergic rhinitis was defined as having nasal symptoms at least 3 months or greater. Allergic rhinitis was defined as having nasal symptoms with the presence of specific IgE by positive skin prick testing or in vitro testing for relevant aeroallergens whereas non-allergic rhinitis showed no evidence of having specific IgE. Other causes of non-allergic rhinitis including druginduced, hormonal and occupational factors were excluded. Written informed consent was obtained from all participants before enrolment. This study was approved by the institutional Review Board at Faculty of Medicine Siriraj Hospital, Mahidol University. The study was registered at http:// Clinicaltrials.gov (#NCT01847131).
All patients had already been treated with budesonide (Bunase  , Okasa Pharma, India), 100 g/spray or equivalent, using 2 sprays in each nostril once daily, and 10 mg cetirizine once daily for at least 2 weeks and still had nasal congestion. Eligible patients were examined by ENT doctors to exclude significant deviated nasal septum or other mechanical obstruction. Then, patients were instructed to record the severity of nasal congestion on a scale of 0 to 3 (0 = no symptom, 1= mild symptoms, 2 = moderate symptoms and 3 = severe symptoms). For 3 days prior to the baseline visit, the seven twice-daily instantaneous (NOW) diary scores 3 (b.i.d. + morning of the baseline visit day) for nasal congestion were required to be 1 or greater to make the patient eligible for randomisation.
The following patients were excluded from the study: patients with a history suggestive of cardiovascular, hepatic or renal diseases, pregnant or lactating women, patients taking oral or nasal decongestants within 7 days, patients treated with immunotherapy, patients with nasal polyps or significant deviated nasal septum and patients with a history of upper respiratory tract infection within 14 days. Skin prick test to aeroallergens was performed. Fifty patients were categorised into 2 groups, 25 in the interventional group and the other 25 in the control group.
Patients were sequentially randomised by patient code numbers generated by the research coordinator who was not directly involved in the process of randomisation. Therefore, investigators and other research assistants were blinded to the interventional drug or matched placebo (an identical placebo containing similar ingredients except for active drug). As shown in Figure 1 , all patients received budesonide (Bunase  , Okasa, India), 100 g/spray Figure 1 . The diagram of study design and treatment regimens. Oxymet, oxymetazoline; INS, intranasal steroid or equivalent, using 2 sprays in each nostril twice daily and continued 10 mg cetirizine once daily. Patients in the interventional group received an additional 0.05% Oxymet nasal spray (Oxymet  , Greater Pharma, Thailand), with 2 sprays in each nostril twice daily for 4 weeks, whereas patients in the control group received placebo for 4 weeks. After 4 weeks, all patients discontinued Oxymet or placebo and continued INS and cetirizine at the same dosage for 2 more weeks. After randomisation, participants were instructed to complete diaries of daily symptoms and recorded nasal peak inspiratory flow (NPIF). The severity of nasal congestion, sneezing and anosmia was recorded in the morning and evening on a 0 to 10 visual analogue scale (0 = no symptoms and 10 = the most severe symptoms). NPIF was measured in litres per minute with "In Check  " portable inspiratory flow meter (Clement Clarke International Ltd, UK). Subjects obtained NPIF 3 times and the best flow performed among the 3 values was recorded every morning and evening. Subjects returned to clinic on days 3, 7, 14, 28 and 42 for a review of their symptom diaries and NPIF record, completion of Rhinoconjunctivitis Quality of Life Questionnaire (Rcq), 10 and replacement of medications.
Statistical analysis
The sample size of 25 patients per group was needed when 5% type I error and 20% type II error were accepted. The data analysed by descriptive statistics were summarised using mean, standard deviation, frequency and percentage. KolmogorovSmirnov test was used to test the data distribution. For normally distributed variables, we used Student's t-test to compare mean of continuous data and Chi-square test to compare the proportion of categorical data between two groups. The data of daily nasal symptom scores were collected on days 3, 7, 14, 28 and 42 according to clinic visits. To minimise the variation of daily nasal symptom score, analysis was performed by using the summation of data at the intervals of days 1-3, 4-7, 8-14, 15-28 and 29-42. Square root transformation of mean nasal symptom scores and NPIF were applied to adjust the data to a normal distribution. Then, the slope of the graphs between the two groups was compared. To examine possible rebound nasal congestion, the paired t-test was used to compare square root of the mean nasal congestion score in the Oxymet group between the last day of treatment (Day 28) and the end of the study (Day 42). To confirm that there was no significant rebound effect, we also compared the data between the first day of treatment (Day 1) and the last day after cessation of therapy (Day 42 
Result
Fifty subjects with chronic rhinitis were recruited into the study. Both groups were comparable at the entry for age, gender, skin test sensitivity and baseline nasal congestion scores ( Table 1) .
Analysis of subjects with chronic rhinitis (N=50)
After the mean nasal congestion scores were transformed to the square root numbers, Oxymet significantly reduced nasal congestion compared with placebo on days 15-28 and 29-42 (p = 0.034 and 0.038, respectively) as shown in Figure 2 . Oxymet also significantly reduced sneezing and anosmia compared with placebo on days 15-28 (p = 0.042 and p = 0.008, respectively). There was no statistically significant difference of NPIF between Oxymet and placebo groups. Both treatment groups led to a significant decrease in the overall domain of Rcq, suggesting a significant clinical improvement. However, there was no significant difference in Rcq scores between both treatment groups at any of the time points.
Analysis of subjects with allergic rhinitis (N=34)
Nasal congestion scores in the Oxymet group significantly improved compared to those in the placebo group on days 4-7, 8-14, 15-28 and 29-42 (p = 0.028, 0.007, 0.001 and 0.006, respectively) as shown in Figure 3 . Anosmia scores in the Oxymet group significantly improved compared to those in There was no statistically significant difference of NPIF between the Oxymet and placebo groups. There was a significant improvement in Rcq scores from the baseline in each treatment group. However, no significant difference in Rcq scores was found between the groups.
Analysis of subjects with non-allergic rhinitis (N=16)
There was no statistically significant difference of nasal symptom scores, NPIF and Rcq between the Oxymet and placebo groups.
Subgroup analysis with post hoc test
Analysis was performed to compare four groups of subjects with allergic or non-allergic rhinitis receiving either Oxymet or placebo, as shown in Tables 2a, 2b 
Analysis of possible rebound nasal congestion
When all subjects with chronic rhinitis in the Oxymet group were analysed, the mean nasal congestion score between day 28 and day 42 showed no significant difference. Nasal congestion score significantly improved at the end of the study (Day 42) compared to the first day of treatment (p < 0.001).
The numbers of adverse events were comparable in both groups, as shown in Table 3 . No lifethreatening adverse events were found.
Discussion
The authors showed a greater effect of the combination of INS and Oxymet on nasal congestion score compared to INS monotherapy. Each group revealed a significant improvement in nasal congestion and Rcq scores at the end of the study compared to baseline, suggesting that no evidence of rhinitis medicamentosa was observed. In subjects with allergic rhinitis, the combined INS and Oxymet worked to a greater extent from the first week of treatment throughout the study compared to those with chronic rhinitis which involved both allergic and non-allergic types. In the Oxymet group, post hoc analysis showed that subjects with allergic rhinitis significantly improved nasal congestion score compared to non-allergic individuals.
Oxymetazoline is an -agonist which directly decreases the oedema of nasal turbinates with duration of action up to 12 hours. Although Oxymet has strong decongestant effects, updated guidelines recommend limiting its use to a few days at most because of concerns of tachyphylaxis and rebound congestion. 1, [11] [12] However, evidences are inconsistent regarding the potential risk of tachyphylaxis with long-term topical decongestant use. Watanabe et al. reported that the use of 0.05% oxymetazoline, using 2 sprays in each nostril 3 times daily, for 4 weeks was not associated with rebound congestion or tachyphylaxis, whereas Yoo et al. showed that use of once nightly Oxymet for 4 weeks did not lead to rhinitis medicamentosa. [13] [14] However, Graf et al. demonstrated that rhinitis medicamentosa developed after the use of Oxymet 3 times daily for 4 weeks. 15 Evidence has shown that the concomitant use of INS with Oxymet can prevent Oxymet-induced rhinitis medicamentosa. 3, [7] [8] In addition, after rhinitis medicamentosa has already developed, INS remains the effective treatment. 9 Therefore, combining INS and Oxymet is intriguing for clinical use since it holds decongestant and anti-inflammatory activities as well as preventing rhinitis medicamentosa. The decreased oedema of the nasal mucosa will also facilitate the access of INS. We conducted the present study using Oxymet twice daily concomitantly with high-dose budesonide and hypothesised that high-dose INS would prevent rhinitis medicamentosa and probably improve nasal symptoms of patients in the placebo group.
In patients with chronic rhinitis who still have residual symptoms despite using INS and oral antihistamine, the guidelines recommend the addition of leukotriene antagonists. 1, 11 However, the efficacy of leukotriene antagonists is rather modest, particularly in patients with refractory nasal congestion. 16 In patients with moderate to severe persistent allergic rhinitis whose symptoms have not improved within 2-4 weeks after using INS and oral antihistamine, the guideline recommends increasing the dose of INS. 11 Our study showed that high-dose INS significantly improved nasal congestion, suggesting that an increased dose of INS could be particularly effective in the short-term. This was consistent with a previous study showing that highdosed fluticasone propionate improved symptom scores and nasal airflow in patients with allergic rhinitis. 4 In more severe cases, our study showed that combined Oxymet and high-dose INS could provide additional benefits. Subjects with allergic rhinitis in our study yielded a greater response to the combined INS and Oxymet compared with those with chronic rhinitis, probably because INS is theoretically effective to treat allergic rhinitis and only subtypes of non-allergic rhinitis including vasomotor rhinitis and NARES (non-allergic rhinitis with eosinophilia syndrome). 1 In the Oxymet group, Oxymet, oxymetazoline; Nasal discomfort includes burning sensation and dryness post hoc analysis showed that subjects with allergic rhinitis significantly improved nasal congestion score compared to non-allergic individuals. This implied that nasal congestion in non-allergic patients was more refractory to treat compared with allergic individuals. Regarding the evaluation for rebound congestion, we compared nasal congestion scores on day 1 vs day 42 as well as day 28 vs day 42. If rhinitis medicamentosa developed in Oxymet group, we would have expected the outcome to be worse compared to the placebo group and to return to baseline after 2 weeks of no treatment. This outcome was not observed. Both treatment groups significantly improved Rcq scores compared with the baseline but there was no significant difference between the two groups. The difference in NPIF between both groups did not reach statistical significance. This is probably due to the disconcordance between patient perception of symptoms and the measurement of Rcq scores as well as NPIF. 17 In accordance with the Cochrane handbook, the process of randomisation using patient code numbers potentially leads to a risk of bias. Therefore, we minimised this issue by cautiously blinding research assistants, investigators, subjects and using well-matched placebo. Further studies with larger numbers of subjects and longer period of follow-up are needed to evaluate Rcq scores, NPIF and the possible rebound congestion or other adverse events.
In summary, the combination of INS and Oxymet provided the advantage beyond INS monotherapy in relieving nasal congestion in subjects with chronic rhinitis. Subjects with allergic rhinitis appeared to have a greater response to the combination compared with those with chronic rhinitis. In the Oxymet group, subjects with allergic rhinitis significantly improved nasal congestion score compared to non-allergic individuals. In addition, the combination of INS and Oxymet was not associated with rhinitis medicamentosa.
